OPN1SW and acute lymphoblastic leukemia: ALCANTARA demonstrated CR or CR with partial hematologic recovery in 16/45 (36%) patients and blinatumomab was also highly effective at eliminating detectable MRD in patients with R/R Ph+ BCP-ALL, as 12/14 (86%) responders achieved a complete MRD response [55].